Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

INTRODUCTION: Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Rheumatol Ther
Autors principals: Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021855/
https://ncbi.nlm.nih.gov/pubmed/31721017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00182-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars